Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Short term Debt: 2022

Historic Short term Debt for C4 Therapeutics (CCCC) over the last 1 years, with Dec 2022 value amounting to $2.3 million.

  • C4 Therapeutics' Short term Debt rose 1278.00% to $10.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $10.3 million, marking a year-over-year increase of 1278.00%. This contributed to the annual value of $2.3 million for FY2022, which is N/A change from last year.
  • Per C4 Therapeutics' latest filing, its Short term Debt stood at $2.3 million for FY2022.
  • In the past 5 years, C4 Therapeutics' Short term Debt ranged from a high of $2.3 million in FY2022 and a low of $2.3 million during FY2022.
  • For the 1-year period, C4 Therapeutics' Short term Debt averaged around $2.3 million, with its median value being $2.3 million (2022).